Brief: Aldeyra Therapeutics Announces PDUFA Extension Of The New Drug Application Of Reproxalap For The Treatment Of Dry Eye Disease
16/12/2025 24:31
Dec 15 (Reuters) - Aldeyra Therapeutics Inc ALDX.O: ALDEYRA THERAPEUTICS ANNOUNCES PDUFA EXTENSION OF THE NEW DRUG APPLICATION OF REPROXALAP FOR THE TREATMENT OF DRY EYE DISEASE ALDEYRA THERAPEUTICS INC - EXTENDED PDUFA TARGET ACTION DATE IS MARCH 16, 2026 Source text: ID:nBw54z2xma Further company coverage: ALDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease
Aldeyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora